Published March 2026
Listen to Audio
This episode features insights from Tina Kiang, PhD, Director of the Division of Regulations and Guidance in the Office of Pharmaceutical Quality (OPQ)/Office of Policy for Pharmaceutical Quality (OPPQ) at the US Food and Drug Administration (US FDA). In a discussion facilitated by David Churchward, Head of Operations Quality Compliance and External Affairs at AstraZeneca, Kiang examines AI at the intersection of regulatory guidance and pharmaceutical innovation, sharing how AI has the potential to reshape the drug lifecycle, the US FDA's current posture and guidance trajectory, how US FDA is currently using AI, and more.
How Is the US Food and Drug Administration (US FDA) Approaching Artificial Intelligence in Pharmaceutical Development and Manufacturing?
In this episode of the ISPE Podcast: Shaping the Future of Pharma, Tina Kiang, PhD, Director of the Division of Regulations and Guidance in the Office of Pharmaceutical Quality (OPQ)/Office of Policy for Pharmaceutical Quality (OPPQ) at the US Food and Drug Administration (US FDA), shares the agency's perspective on the growing role of artificial intelligence (AI) across the pharmaceutical product lifecycle.
In a conversation facilitated by David Churchward, Head of Operations Quality Compliance and External Affairs at AstraZeneca, Kiang explores how AI is being applied in drug development, pharmaceutical manufacturing, quality oversight, regulatory submissions, and post-market surveillance. She discusses the US FDA's evolving guidance framework, the importance of risk-based implementation strategies, and why human accountability must remain at the center of AI-enabled decision-making.
The discussion also examines emerging opportunities for AI to accelerate innovation, improve process understanding, strengthen quality systems, and support regulatory science, while highlighting the guardrails needed to maintain patient safety, product quality, and public trust.
Listen to this episode to learn:
- How AI is being used across drug development, manufacturing, and regulatory processes
- Why the US FDA believes existing current good manufacturing practice frameworks can support AI integration
- How AI can improve process monitoring, investigations, and operational efficiency
- Why human oversight remains essential, even in highly automated environments
- Best practices for AI model validation, change control, and lifecycle management
- The importance of data governance, data quality, and minimizing model bias
- How AI can support post-market surveillance and identification of safety signals
- What pharmaceutical companies should consider when preparing for inspections involving AI-enabled systems
- Why early engagement with regulators is critical when implementing novel AI applications
Who Should Listen?
This episode is ideal for:
- Pharmaceutical quality professionals
- Manufacturing and process development teams
- Regulatory affairs and chemistry, manufacturing, and controls professionals
- Quality assurance and quality systems leaders
- Digital transformation and AI program leaders
- Pharmaceutical engineers and technical operations teams
- Compliance and inspection readiness professionals
- Anyone interested in the future of AI in pharmaceutical development, manufacturing, and regulation
As regulatory expectations for AI continue to evolve, collaboration between industry and health authorities will be critical to enabling innovation while maintaining quality, safety, and compliance. Explore ISPE's Regulatory Operations initiatives and resources to stay informed about emerging regulatory trends, industry guidance, and opportunities for engagement.
Learn More About ISPE Regulatory Operations
Frequently Asked Questions
How is AI being used in the pharmaceutical industry?
AI is being applied across the pharmaceutical lifecycle, including molecule selection, clinical trial design, manufacturing process control, deviation investigations, quality monitoring, regulatory submissions, and post-market surveillance. AI's ability to analyze large volumes of data and identify patterns can help organizations improve efficiency and enhance decision-making.
Does the US FDA believe new regulations are needed for AI in pharmaceutical manufacturing?
According to Kiang, the current regulatory framework is generally flexible enough to accommodate AI technologies. However, additional guidance is being developed to help industry understand how AI and machine learning should be implemented within pharmaceutical quality and manufacturing systems.
Will AI replace human decision-making in regulated pharmaceutical environments?
No. A key theme throughout the discussion is that AI provides outputs, while humans make decisions. Organizations remain responsible for evaluating AI-generated information, maintaining oversight, and ensuring quality and compliance expectations are met.
What are the biggest risks associated with AI adoption in pharma?
Potential risks include poor-quality training data, model bias, hallucinations, lack of transparency, inadequate validation, uncontrolled model changes, and insufficient governance. Organizations should establish clear control strategies, monitoring plans, and accountability frameworks before deploying AI systems.
What should companies consider when validating AI models?
Companies should ensure models are fit for their intended use, supported by appropriate training and validation data, monitored for performance drift, and incorporated into existing quality and change control processes. Risk assessments, predefined triggers, and periodic review activities are critical components of an effective AI governance strategy.
How can AI improve pharmaceutical manufacturing?
AI can support advanced manufacturing by analyzing process data in real time, identifying trends, detecting deviations earlier, optimizing process parameters, and enhancing root cause investigations. These capabilities can help improve process robustness and product quality while supporting continuous improvement initiatives.
References
- US FDA and European Medicines Agency. Guiding Principles of Good AI Practice in Drug Development.
- US FDA. "Artificial Intelligence for Drug Development."
- US FDA, Center for Drug Evaluation and Research (CDER). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.
- US FDA, CDER Guidance Agenda.
